The HHS peptide policy explained: what RFK Jr. signed in 2026

On 28 October 2026, HHS Secretary Robert F. Kennedy Jr. signed an interim policy saying HHS will not take enforcement action against 503A pharmacies that compound six peptides (BPC-157, TB-500, MOTS-c, Semax, Epitalon and KPV) under ten conditions (Federal Register 2026-22192). It was published 30 October. It is not FDA approval, and HHS can withdraw it.

Compounded drugs are not FDA-approved, and this policy is interim; everything below was checked on 30 October 2026 against the Federal Register notice and the full policy on hhs.gov. For each peptide's status in one table, see the peptide legal status tracker.

What the HHS peptide policy says

The Federal Register notice is short. Its core sentence: "HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A" (Federal Register). The notice gives the reason as "to expand and improve patient access", and it is issued by the Office of the Secretary, with the Office of the Assistant Secretary for Health as contact, not by FDA.

The full policy sits in a separate document on hhs.gov. It states that the Secretary "has determined that the policy advances patient choice and freedom while appropriately protecting patient safety" (HHS policy). It runs until FDA finishes rulemaking on each peptide: "Until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list" (HHS policy).

The six peptides and their routes

Source: Appendix B of the HHS policy. Emideltide (DSIP), reviewed by FDA's advisory committee in July, was left out. Peptide guides: BPC-157, TB-500, MOTS-c, Semax, Epitalon, KPV.

The ten conditions

HHS's restraint applies only "when all of the following circumstances are present". In plain words:

1. Listed peptide. The ingredient is one of the six in Appendix A.
2. Exact identity and route. It matches the amino acid sequence, salt form and route limits in Appendix B.
3. Tested ingredient. The ingredient comes from an FDA-registered facility with a valid certificate of analysis covering identity, purity, potency and contaminants such as endotoxins and heavy metals.
4. Traceable maker. The original manufacturer, not just a repacker or distributor, is FDA-registered, follows current good manufacturing practice, and its facility address is on the certificate.
5. Reporting. The pharmacy reports what it compounds, serious adverse events and quality problems to FDA's MedWatch program and to the states involved.
6. Label. The product carries the statement "This is a compounded drug product. Not for resale." (HHS policy)
7. One peptide per product. "The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A" (HHS policy).
8. Oral products need absorption evidence. A pharmacy making an oral form must keep documentation that the formulation achieves adequate oral bioavailability in humans.
9. Simple device only. The only delivery device allowed with the product is an FDA 510(k)-cleared syringe.
10. Everything else in the law still applies, including no insanitary conditions and the patient-specific prescription requirement of section 503A.

Condition 7 rules out blends such as BPC-157 with TB-500; HHS says single-ingredient products make adverse events easier to attribute. Our compounded peptide safety guide explains how to ask a program about conditions 3 to 5.

What the policy does not do

• It does not approve anything. The notice repeats FDA's standard line: "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed" (Federal Register).
• It creates no rights. The policy "does not establish any rights for any person and is not binding on HHS or the public" (Federal Register).
• It does not put the peptides on the 503A bulks list. That needs FDA rulemaking, which the notice says "may propose adding some or all of these peptides" (Federal Register).
• It is written for 503A compounding only. It does not mention 503B outsourcing facilities, which make larger batches without individual prescriptions.
• It does not cover research-use-only sellers. FDA continues to treat those products as unapproved drugs; see research vs prescription peptides.
• It does not change state law. State boards of pharmacy keep their own powers, so access may differ by state.
• It does not cover other peptides. Ipamorelin, CJC-1295, LL-37, injectable GHK-Cu, melanotan II and others stay outside it.

Why HHS says it acted

HHS frames the policy as a safer alternative to the gray market. The policy says it "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients" (HHS policy). It also cites the July 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, which reviewed seven peptides over two days (FDA meeting page).

FDA's own reviewers disagreed. For each of the six, HHS's appendix records that FDA's Center for Drug Evaluation and Research recommended against listing the substance, while the committee voted in favor. HHS then gives its reasons for overriding that advice: new certificates of analysis, documented compounding use, and the safeguards in the ten conditions. FDA's earlier safety notes remain public; for BPC-157 it wrote that it "lacks sufficient information to know whether the drug would cause harm when administered to humans" (FDA).

RFK Jr., peptides and the "war on peptides"

Kennedy signed the notice himself, and it came from his office rather than from FDA. That is the documented part. The phrase "war on peptides" is used widely in coverage and by peptide advocates to describe FDA's September 2023 decision to place BPC-157 and other peptides in Category 2. We could not find a primary transcript or HHS document in which Kennedy uses those words, so we do not attribute the phrase to him.

The 2023 placements are on record. HHS's appendix says TB-500 "was in Category 2 from September 29, 2023, until April 22, 2026" (HHS policy), and FDA's meeting notice for the July review was published on 16 April 2026 (Federal Register 2026-07361).

Comment period

The notice states: "Written comments can be submitted until 2 weeks after date of publication in the Federal Register" (Federal Register). Publication was 30 October 2026, and the Federal Register's docket data shows a comment end date of 14 November 2026. Comments go to docket HHS-OASH-2026-0496 on regulations.gov. The Federal Register calls the document a draft policy in its background section, so HHS may revise it after comments.

What could change next

• A safety or quality problem. HHS "may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises" (Federal Register).
• FDA rulemaking. A final rule adding a peptide to the 503A bulks list would replace the interim cover; a rule leaving it off would end it.
• Revisions after comments. The draft label means the conditions or the list could shift.
• More peptides under review. FDA plans to consult its advisory committee on GHK-Cu "before the end of February 2027" (FDA category list).
• Leadership. The policy creates no rights, so a future Secretary could withdraw it without a rulemaking.

What it means if you want one of these peptides

A licensed telehealth program can now prescribe the six through a 503A pharmacy, within the conditions. Prices on this site start at $149 a month for BPC-157, $149 for TB-500 and $199 for MOTS-c. Superpower, from $149, opened preorders the same week and tells buyers its "initial BPC-157, TB-500 and MOTS-c products are not FDA-approved" (Superpower); see our Superpower review. Ask any program which pharmacy fills the order and whether its ingredient certificates meet the policy. We do not publish doses.

FAQ

What is the HHS peptide policy?

The HHS peptide policy is an interim enforcement-discretion policy signed by Secretary Robert F. Kennedy Jr. on 28 October 2026 and published 30 October. HHS says it will not take enforcement action against state-licensed 503A pharmacies, federal facilities or licensed physicians compounding BPC-157, TB-500, MOTS-c, Semax, Epitalon or KPV, provided ten conditions are met. The products remain unapproved by FDA.

What did RFK Jr. do on peptides?

Kennedy, as HHS Secretary, signed the enforcement-discretion notice that lets 503A pharmacies compound six peptides on prescription without federal enforcement, under conditions. The policy came from the Office of the Secretary rather than FDA, and HHS's appendix records that FDA's drug center had recommended against listing each of the six. HHS describes the move as advancing patient choice and freedom.

What is the "war on peptides"?

"War on peptides" is a phrase used in coverage and by advocates for FDA's September 2023 move of BPC-157 and other peptides into Category 2, which signaled possible enforcement against pharmacies compounding them. We found no primary transcript or HHS document showing Kennedy using the phrase, so we do not attribute it to him. The October 2026 policy reversed part of that 2023 position.

Does the HHS policy make peptides FDA-approved?

No. The notice itself says compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality before marketing. The policy is a statement that HHS will not enforce in certain circumstances. It does not add the peptides to the 503A bulks list, which requires FDA rulemaking, and it creates no rights for anyone.

When does the comment period close?

Comments may be submitted for two weeks after publication on 30 October 2026, and the Federal Register's docket data lists 14 November 2026 as the end date. Comments go to docket HHS-OASH-2026-0496 on regulations.gov. The notice calls the document a draft policy, so HHS could revise its conditions or list after reviewing comments.

Does the policy cover 503B outsourcing facilities?

The policy is written for 503A compounding by state-licensed pharmacies, federal facilities and licensed physicians filling patient-specific prescriptions. It does not mention 503B outsourcing facilities, which compound in bulk without individual prescriptions. Condition 10 also keeps the 503A patient-specific prescription requirement in force, so office stock and wholesale batches fall outside it.

Can the HHS peptide policy be withdrawn?

Yes. HHS says it may revisit the policy in whole or in part if a safety signal or product quality issue arises, and the policy states it is not binding on HHS. For each peptide it also ends once FDA issues a final rule on the 503A bulks list. A future Secretary could withdraw it without new rulemaking.

Compare licensed programs for the six peptides, with full monthly prices, on the best programs page or the BPC-157 cost page.